--- title: "ZyVersa Therapeutics (ZVSA) news: delisting" url: "https://aibio.space/companies/zyversa-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ZVSA delisting news: Nasdaq files Form 25 to delist ZyVersa Therapeutics common stock. ZyVersa Therapeutics, Inc. (OTC: ZVSA), United States." --- ZVSA ZyVersa Therapeutics, Inc. OTC · United States # ZyVersa Therapeutics (ZVSA) news ZVSA delisting news Company Updates · 2026-07-08 ## [ZyVersa director resigns as company explores cost cuts](https://aibio.space/news/zyversa-director-resigns-company-explores-cost-cuts/) ZyVersa said a director has resigned and that it is considering cost reductions, pay cuts for two officers and possible sales of its VAR 200 or IC 100 candidates while it seeks to raise capital. ## Latest ZyVersa Therapeutics news 1. 2025-10-06 Listings [Nasdaq files Form 25 to delist ZyVersa Therapeutics common stock](https://aibio.space/news/nasdaq-files-form-25-delist-zyversa-therapeutics-common-stock/) The Nasdaq Stock Market LLC filed the notice with the SEC on October 6, 2025, citing the rule an exchange uses to remove a security. 2. 2025-09-18 Listings [Nasdaq to complete delisting of ZyVersa Therapeutics stock with Form 25 filing](https://aibio.space/news/nasdaq-complete-delisting-zyversa-therapeutics-stock-form-25-filing/) Nasdaq told ZyVersa it would announce the delisting on September 18, 2025. The shares have traded on the OTCQB Venture Market since July 28, 2025. ## ZyVersa Therapeutics at a glance - **Ticker**: ZVSA - **Listing**: OTC - **Country**: United States - **Cash, Mar 31, 2026**: $302,660 ### Related companies - [AIM ImmunoTech](https://aibio.space/companies/aim-immunotech/) AMEX: AIM - [Syros Pharmaceuticals](https://aibio.space/companies/syros-pharmaceuticals/) OTC: SYRS - [Rein Therapeutics](https://aibio.space/companies/rein-therapeutics/) NASDAQ: RNTX - [Tarsus Pharmaceuticals](https://aibio.space/companies/tarsus-pharmaceuticals/) NASDAQ: TARS - [Trevena](https://aibio.space/companies/trevena/) OTC: TRVN - [Atossa Therapeutics](https://aibio.space/companies/atossa-therapeutics/) NASDAQ: ATOS - [AN2 Therapeutics](https://aibio.space/companies/an2-therapeutics/) NASDAQ: ANTX - [Rafarma Pharmaceuticals, Inc. (WY)](https://aibio.space/companies/rafarma-pharmaceuticals-wy/) OTC: RAFA ### Also on OTC - [TRAFALGAR INTERNATIONAL, INC.](https://aibio.space/companies/trafalgar-international-gcand/) GCAND - [Therapeutic Solutions International](https://aibio.space/companies/therapeutic-solutions-international/) TSOI - [Protagenic Therapeutics](https://aibio.space/companies/protagenic-therapeutics/) PTIX - [ALR Technologies SG](https://aibio.space/companies/alr-technologies-sg/) ALRTF - [America Great Health](https://aibio.space/companies/america-great-health/) AAGH - [BioXcel Therapeutics](https://aibio.space/companies/bioxcel-therapeutics-btai/) BTAI ## What ZyVersa Therapeutics does ZyVersa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing drugs for patients with chronic renal or inflammatory diseases. It holds two globally licensed platforms, both discovered by researchers at the University of Miami Miller School of Medicine. The first is VAR 200, a Cholesterol Efflux Mediator, an injectable form of 2-hydroxypropyl-beta-cyclodextrin for renal diseases, licensed from L&F Research LLC on December 15, 2015. Its lead indication is focal segmental glomerulosclerosis (FSGS), an orphan disease that the text says affects approximately 40,000 people in the United States. The company plans a Phase 2a basket trial in FSGS and Alport syndrome patients in Q2-2026. The second is IC 100, a humanized monoclonal antibody described as an inflammasome ASC inhibitor, in preclinical development for chronic inflammatory diseases. Its lead indication is cardiometabolic conditions associated with obesity. The company plans an IND submission for IC 100 in Q4-2026, followed by a Phase 1 trial in healthy overweight patients with a BMI between 27 – 30. The text notes that chronic kidney disease affects over 750 million people worldwide. | Product or program | What it is | Stage | |---|---|---| | VAR 200 | Injectable cholesterol efflux mediator for renal diseases, lead indication FSGS | Clinical development; Phase 2a basket trial planned for Q2-2026 | | IC 100 | Humanized monoclonal antibody inhibiting the inflammasome ASC component, for inflammatory conditions | Preclinical development; IND submission planned for Q4-2026 | Summarised from the company's [10-K filed Mar 31, 2026](https://www.sec.gov/Archives/edgar/data/1859007/000149315226014271/form10-k.htm). ## ZyVersa Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$1.1 million](https://www.sec.gov/Archives/edgar/data/1859007/000149315226014271/) | [$1.8 million](https://www.sec.gov/Archives/edgar/data/1859007/000149315226014271/) | | Net income (loss) | [-$25.0 million](https://www.sec.gov/Archives/edgar/data/1859007/000149315226014271/) | [-$9.4 million](https://www.sec.gov/Archives/edgar/data/1859007/000149315226014271/) | | Cash from operations | [-$5.1 million](https://www.sec.gov/Archives/edgar/data/1859007/000149315226014271/) | [-$7.5 million](https://www.sec.gov/Archives/edgar/data/1859007/000149315226014271/) | | Cash and equivalents | [$101,778](https://www.sec.gov/Archives/edgar/data/1859007/000149315226022759/) | [$1.5 million](https://www.sec.gov/Archives/edgar/data/1859007/000149315226022759/) | Latest balance sheet, Mar 31, 2026 (10-Q): cash and equivalents $302,660. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about ZyVersa Therapeutics Was ZyVersa Therapeutics delisted? Our latest story on this, dated Oct 6, 2025: "Nasdaq files Form 25 to delist ZyVersa Therapeutics common stock". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/nasdaq-files-form-25-delist-zyversa-therapeutics-common-stock/). What is the ticker symbol of ZyVersa Therapeutics? ZyVersa Therapeutics, Inc. trades under the ticker ZVSA on OTC. Where is ZyVersa Therapeutics listed? ZyVersa Therapeutics, Inc. is listed on OTC. What is the SEC CIK of ZyVersa Therapeutics? The SEC Central Index Key (CIK) for ZyVersa Therapeutics, Inc. is 1859007. Its filings are on SEC EDGAR. How many shares does ZyVersa Therapeutics have outstanding? 8,095,921 shares as of 2026-05-11, per the cover page of its 10-Q filed 2026-05-13. Which country or territory is ZyVersa Therapeutics listed under? Our directory records ZyVersa Therapeutics, Inc. under United States. What does ZyVersa Therapeutics do? Our directory classifies ZyVersa Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of ZyVersa Therapeutics? The ISIN recorded for ZyVersa Therapeutics, Inc. is US98987D3008. Does aibio.space cover ZyVersa Therapeutics? aibio.space lists ZyVersa Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is ZyVersa Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What does ZyVersa Therapeutics develop? ZyVersa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing drugs for patients with chronic renal or inflammatory diseases. It holds two globally licensed platforms, both discovered by researchers at the University of Miami Miller School of Medicine. What is VAR 200 from ZyVersa Therapeutics? VAR 200: Injectable cholesterol efflux mediator for renal diseases, lead indication FSGS Stage: Clinical development; Phase 2a basket trial planned for Q2-2026. What is IC 100 from ZyVersa Therapeutics? IC 100: Humanized monoclonal antibody inhibiting the inflammasome ASC component, for inflammatory conditions Stage: Preclinical development; IND submission planned for Q4-2026. Is ZyVersa Therapeutics profitable? ZyVersa Therapeutics, Inc. reported a net loss of $25.0 million for the fiscal year ended Dec 31, 2025, and used $5.1 million of cash in operations, per its annual report to the SEC. How much does ZyVersa Therapeutics spend on research and development? $1.1 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: ZyVersa Therapeutics Members talk about ZyVersa Therapeutics (ZVSA). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at ZyVersa Therapeutics, newest first. Each line links the filing it comes from. 1. 2025-11-14 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1859007/000149315225023612/formnt10-q.htm) 2. 2025-10-06 Listings Filed to remove its shares from exchange listing. SEC Form 25-NSE. [Source](https://www.sec.gov/Archives/edgar/data/1859007/000135445725000988/xslF25X02/primary_doc.xml) 3. 2025-09-18 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1859007/000149315225013968/form8-k.htm) 4. 2025-07-16 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1859007/000164117225019856/form8-k.htm) 5. 2025-06-25 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1859007/000164117225016388/ex99-1.htm) 6. 2025-05-30 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1859007/000164117225013038/form8-k.htm) 7. 2025-04-07 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1859007/000164117225003034/form8-k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:ZVSA on TradingView](https://www.tradingview.com/symbols/OTC-ZVSA/). ## SEC filings and registration - **SEC name**: ZyVersa Therapeutics, Inc. - **CIK**: 1859007 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ZVSA (OTC) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company
Emerging growth company - **Business address**: 2436 NORTH FEDERAL HIGHWAY, LIGHTHOUSE POINT, FL, 33064 - **Phone**: 908-370-5102 - **Shares outstanding**: 8,095,921 as of 2026-05-11 (10-Q filed 2026-05-13) - **Former names**: Larkspur Health Acquisition Corp. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1859007/000149315226033565/form8-k.htm) filed 2026-07-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1859007/000149315226032851/form8-k.htm) filed 2026-07-10 - [10-Q](https://www.sec.gov/Archives/edgar/data/1859007/000149315226022759/form10-q.htm) filed 2026-05-13 - [10-K](https://www.sec.gov/Archives/edgar/data/1859007/000149315226014271/form10-k.htm) filed 2026-03-31 - [8-K](https://www.sec.gov/Archives/edgar/data/1859007/000149315226008994/form8-k.htm) filed 2026-03-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1859007/000149315225025966/form8-k.htm) filed 2025-12-03 - [8-K](https://www.sec.gov/Archives/edgar/data/1859007/000149315225024273/form8-k.htm) filed 2025-11-19 - [10-Q](https://www.sec.gov/Archives/edgar/data/1859007/000149315225024263/form10-q.htm) filed 2025-11-19 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001859007), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details ZyVersa Therapeutics, Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker ZVSA, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: ZyVersa Therapeutics, Inc. - **Ticker**: ZVSA - **Listing**: OTC - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US98987D3008 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/OTC-ZVSA/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/zyversa-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "ZyVersa Therapeutics (ZVSA) news: delisting", 2026-10-31, https://aibio.space/companies/zyversa-therapeutics/